Why Do Investors Buy Stock In Iovance Biotherapeutics Inc. (IOVA)?
Iovance Biotherapeutics Inc. (NASDAQ:IOVA) has a beta value of 0.85 and has seen 6.38 million shares traded in the last trading session. The company, currently valued at $3.54B, closed the last trade at $23.45 per share which meant it gained $0.31 on the day or 1.34% during that session. The IOVA stock price is -131.17% off its 52-week high price of $54.21 and 32.28% above the 52-week low of $15.88. If we look at the companys 10-day average daily trading volume, we find that it stood at 4.78 million shares traded. The 3-month trading volume is 3.73 million shares. The consensus among analysts is that Iovance Biotherapeutics Inc. (IOVA) is an Overweight stock at the moment, with a recommendation rating of 2.10. 0 analysts rate the stock as a Sell, while 1 rate it as Overweight. 3 out of 14 have rated it as a Hold, with 10 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -$0.51. Iovance Biotherapeutics Inc. (NASDAQ:IOVA) trade information  Sporting 1.34% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on Friday, 06/11/21 when the IOVA stock price touched $23.45 or saw a rise of 0.42%. Year-to-date, Iovance Biotherapeutics Inc. shares have moved -49.46%, while the 5-day performance has seen it change 30.86%. Over the past 30 days, the shares of Iovance Biotherapeutics Inc. (NASDAQ:IOVA) have changed -10.08%. Short interest in the company has seen 22.33 million shares shorted with days to cover at 3.85. Wall Street analysts have a consensus price target for the stock at $40.08, which means that the shares value could jump 41.49% from current levels. The projected low price target is $18.00 while the price target rests at a high of $83.00. In that case, then, we find that the current price level is -253.94% off the targeted high while a plunge would see the stock lose 23.24% from current levels. Iovance Biotherapeutics Inc. (IOVA) estimates and forecasts  Figures show that Iovance Biotherapeutics Inc. shares have underperformed across the wider relevant industry. The companys shares have lost -49.22% over the past 6 months, with this year growth rate of -10.11%, compared to 8.70% for the industry. Other than that, the company has, however, lowered its growth outlook for the 2021 fiscal year revenue. Growth estimates for the current quarter are -8.50% and -30.00% for the next quarter. If we evaluate the companys growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -24.70% over the past 5 years. IOVA Dividends  Iovance Biotherapeutics Inc. is expected to release its next earnings report in July this year, and investors are excited at the prospect of better dividends despite the companys debt issue. 5 Stocks Under $10 That Are Poised to Take Off Investing in stocks under $10 could significantly increase the returns on your portfolio, especially if you pick the right stocks! Within this report you will find 5 top stocks that offer investors huge upside potential and the best bang for their buck. Investing in stocks under $10 could significantly increase the returns on your portfolio, especially if you pick the right stocks! Within this report you will find 5 top stocks that offer investors huge upside potential and the best bang for their buck. Add them to your watchlist before they take off! Get the Top 5 Stocks Now! Sponsored  Iovance Biotherapeutics Inc. (NASDAQ:IOVA)s Major holders  Insiders own 0.62% of the company shares, while shares held by institutions stand at 106.74% with a share float percentage of 107.40%. Investors are also buoyed by the number of investors in a company, with Iovance Biotherapeutics Inc. having a total of 359 institutions that hold shares in the company. The top two institutional holders are ARK Investment Management, LLC with over 19.73 million shares worth more than $624.55 million. As of Mar 30, 2021, ARK Investment Management, LLC held 12.91% of shares outstanding. The other major institutional holder is Vanguard Group, Inc. (The), with the holding of over 12.05 million shares as of Mar 30, 2021. The firms total holdings are worth over $381.61 million and represent 7.89% of shares outstanding. Also the top two Mutual Funds that are holding companys shares are ARK ETF Tr-ARK Innovation ETF and ARK ETF Tr-ARK Genomic Revolution ETF. As of Apr 29, 2021, the former fund manager holds about 7.41% shares in the company for having 11.33 million shares of worth $356.31 million while later fund manager owns 7.62 million shares of worth $241.15 million as of Mar 30, 2021, which makes it owner of about 4.98% of companys outstanding stock.